| 摘要 |
PROBLEM TO BE SOLVED: To provide methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA).SOLUTION: The methods include subcutaneously administering an anti-IL-6 receptor (IL-6R) antibody to a patient, where the anti-IL-6R antibody is administered as a fixed dose of 162 mg per dose. Preferably, the anti-IL-6R antibody is tocilizumab. |
